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MicroRNAs (miRNAs) are made up of -22 endogenous nucleotides and are small, noncoding RNAs that are important regulators of 
gene expression at the posttranscriptional level by degrading or repressing target miRNAs. miRNA expression profiles can be used 
for the detection of diagnostic and prognostic markers for various cancers. Also, alterations of miRNAs in cancer tissues have been 
associated with clinicopathological parameters. Along with circulating miRNAs, tissue miRNAs have shown promise as markers that can 
predict cancer recurrence and/or the potential for survival of cancer patients. Additionally, some miRNAs have therapeutic potential. In 
this review, we discuss and assess the usefulness of tissue-derived and circulating miRNAs for the diagnosis and prognosis of prostate 
cancer. 
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INTRODUCTION
Prostate cancer is the most common form of cancer for males 
in Western countries, and the incidence is increasing in many 
of those countries [1]. Early diagnosis of cancer and timely 
detection of disease progression following either radical pros-
tatectomy or radiation therapy are crucial for the effective 
treatment of prostate cancer and for a beneficial clinical out-
come. To increase the detection rate of early-stage prostate 
cancer, there has been much research to develop effective 
biomarkers. Currently, measurement of serum prostate-spe-
cific antigen (PSA) is the most common tool used to detect 
prostate cancer. PSA levels correlate with prostate cancer risk, 
aggressiveness, and outcome [2]. Although PSA is considered 
to be the most useful biomarker for prostate cancer [3,4], it has 
limitations such as a low detection rate for prostate cancer in 
the so-called gray zone (PSA, 4–10 ng/mL) and no advantage 
of PSA screening for a control group [5]. Moreover, the benefit 
of mass screening by PSA testing and the establishment of 
systemized surveillance protocols according to PSA levels are 
still under debate. Also, although PSA screening has reduced 
the mortality rate of prostate cancer, it is often associated 
with over-diagnosis [6]. Thus, there has been rapidly growing 
interest in alternative biomarkers for prostate cancer, such as 
microRNAs (miRNAs).
 miRNAs are made up of -22 endogenous nucleotides and 
are small, noncoding RNAs that are important regulators of 
gene expression at the post-transcriptional level because they 
degrade, or repress, target mRNAs [7]. miRNAs could play im-
portant roles in various processes such as cell development, 
differentiation, proliferation, cell-cycle control, apoptosis, 
and metabolism [7]. The expression of miRNAs can be influ-
enced by chromosomal rearrangements (deletions, amplifi-
cations, and mutations), promoter methylation, and regula-
tion of transcription. Aberrations can result in miRNA up- and 
down-regulation. Additionally, a single miRNA can target 
hundreds of mRNAs. Hence, miRNA alterations are known 
to disrupt the expression of several mRNAs and proteins, and 
can be involved in the occurrence of various human cancers 
[8-10]. 
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 There have been many reports about disease-specific 
miRNA expression profiles in various human cancers [11-
16]. The miRNA expression profiling of human cancers is 
increasing in importance due to its usefulness in diagnosis, 
staging, progression, prognosis, and response to treatment. 
Consequently, miRNAs are being regarded as new oncogenes 
or tumor suppressor genes and new biomarkers for the di-
agnosis and prediction of treatment response and prognosis. 
Recently, several studies have demonstrated that miRNAs are 
sufficiently stable after being subjected to severe conditions, 
such as boiling, very low or high pH, extended storage, and 
several freeze-thaw cycles, and they are well protected from 
Ribonuclease in blood serum and plasma, as well as from ex-
posure to other body fluids [17-19]. Therefore, stability makes 
miRNA levels well suited for testing in patient samples. In this 
review, we discuss and assess the usefulness of tissue-derived 
and circulating miRNAs for the diagnosis and prognosis of 
prostate cancer. 
miRNAs AS BIOMARKERS IN SOLID  
TUMORS
miRNA expression profiles in various cancer tissues can be 
diagnostic and prognostic markers of each cancer. Several 
studies have demonstrated the up- and down-regulation of 
miRNAs associated with cancer pathogenesis [14,16]. He 
et al. [14] found that three miRNAs (miR-221, miR-222, and 
miR-146) were transcriptionally up-regulated in papillary 
thyroid carcinoma compared to normal thyroid tissue. They 
suggested that the up-regulation of these miRNAs is involved 
in thyroid carcinogenesis. Also, Volinia et al. [16] demonstrated 
21 miRNAs that were up-regulated in six solid cancer tissues. 
They found predicted targets, which included the tumor sup-
pressing genes RB1 and TGFBR2. They suggested that miR-
NAs are extensively involved in the tumorigenesis of solid tu-
mors and that they support this function as either dominant 
or recessive cancer genes.
 Alterations of miRNA in cancer tissues have been associ-
ated with the clinicopathological parameters of each cancer. 
Yanaihara et al. [15] showed that miRNA expression profiles 
of lung cancer were correlated with the survival of lung can-
cer patients. Both high miR-155 and low miR-let-7a-2 expres-
sion are associated with poor survival. Murakami et al. [13] 
showed that three miRNAs (miR-224, miR-18, and precursor 
miR-18) demonstrated a higher expression in the hepatocel-
lular carcinoma (HCC) samples, and that five miRNAs (miR-
199a, miR-199a*, miR-200a, miR-125a, and miR-195) dem-
onstrated a lower expression in the HCC samples in miRNA 
expression profiles between HCC and nontumorous tissue. 
They also reported expression levels of some miRNAs that 
were inversely correlated with the degree of HCC differen-
tiation. Iorio et al. [12] demonstrated miRNA expressions of 
miR-125b, miR-145, miR-21, and miR-155 that were deregu-
lated significantly in miRNA expression profiles of breast can-
cer tissues, and they identified miRNAs with expressions that 
were correlated with specific breast cancer biopathologic fea-
tures such as estrogen and progesterone receptor expression, 
tumor stage, vascular invasion, or proliferation index. In this 
regard, miRNA expression profiles of cancer tissues could be 
postulated as useful markers for the diagnosis and prognosis 
of various cancer patients. 
 Recently, tumor-derived circulating exosomes, including 
miRNAs in ovarian cancer, have shown similarities with cel-
lular miRNAs [20]. Moreover, in another study, circulating 
exosomal miRNAs have been correlated with tumor miRNA 
levels in lung cancer [21]. These results suggest that circulat-
ing exosomal miRNAs could potentially be used as diagnostic 
markers for screening in asymptomatic populations. More 
recently, circulating miRNAs were analyzed for promising 
markers to detect early cancers such as colon cancer and 
pancreatic cancer [22,23]. When comparing the miRNAs in 
plasma between cancer patients and healthy controls, re-
searchers found novel noninvasive biomarkers (miR-29a and 
miR-92a in colon cancer and miR-210 in pancreatic cancer) 
that were useful for early detection. Resnick et al. [24] dem-
onstrated that circulating miRNAs (miR-21, miR-92, and miR-
93) as diagnostic markers in ovarian cancer might be more 
feasible than established serum-based screening markers 
such as CA-125. These results indicate that circulating miR-
NAs might be noninvasive diagnostic markers compared with 
established clinical diagnostic tests that are invasive.
 It is noteworthy that circulating miRNAs could be a useful 
marker for follow-up after treatment. Yamamoto et al. [25] 
found that the expression of miR-500, an oncofetal miRNA, 
changed during liver development in liver cancer. They also 
showed that miR-500 was abundantly expressed in 45% of 
human HCC tissue. Notably, in the sera of HCC patients, the 
amount of miR-500 was increased. Furthermore, elevated 
miR-500 in HCC patients returned to normal serum levels 
after surgery. These results reveal that the miR-500 in the se-
rum of the HCC patients might be an oncofetal miRNA that 
reflects pathological conditions. In addition, Wong et al. [26] 
demonstrated that miR-184 in squamous cell carcinoma also 
acted similar to miR-500 in HCC. Feng et al. [27] also showed 
that circulating RNA levels in renal cell carcinoma patients 
were significantly higher than normal controls and were re-
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duced after nephrectomy. Several reports have suggested that 
the identified circulating miRNAs might be valuable biomark-
ers for cancer detection [24,28]. However, miRNAs in tissues 
show promise as markers that can predict cancer recurrence 
and the survival of cancer patients [29,30]. 
miRNAs IN PROSTATE CANCER
Molecular alterations such as chromosomal instability, epi-
genetic silencing, alteration of tumor-suppressor genes, and 
some protein expressions are associated with the tumorigen-
esis of prostate cancer [31,32]. Furthermore, aberrant elec- 
troretinogram (ERG) expression, loss of phosphatase and 
tensin homolog (PTEN), and inactivation of CD9 promotes 
the progression of prostate cancer [33,34]. In addition, andro-
gen receptor signaling is very important in the progression to 
castration-resistant prostate cancer [35]. Interestingly, these 
genetic alterations in cancer play important roles in the spe-
cific activity of miRNA. In prostate cancer, 30% of epigenetic 
silencing regions contained the loci of miRNAs [36]. DNA 
methylation of a promoter region and p53 mutation leads to a 
down-regulation of miRNA [37]. Sun et al. [38] reported simi-
lar results. They analyzed the expression patterns of miRNA 
target genes in public microarray datasets. They inferred a 
general overexpression of miRNAs in prostate cancer based 
on the reduced abundance of putative miRNA targets in hu-
man prostate cancer. Furthermore, Xu et al. [39] found that 
functional polymorphism in the pre-miR-146a of prostate 
cancer tissue affects the amount of miR-146a, and is associ-
ated with prostate cancer risk. 
 The expression of specific miRNAs could be a classifier that 
could be used to differentiate between normal and cancer 
tissues. However, differences in the expression patterns of 
miRNAs that have been reported in different studies, which 
creates controversy in their use as classifiers. In fact, Volinia et 
al. [16] demonstrated that miR-21, miR-17-5p, miR-191, miR-
29b-2, miR-199a-1, miR-146, miR-181b-1, miR-20a, miR-32, 
miR-92-2, miR-214, miR-30c, miR-25, and miR-106a all were 
up-regulated in prostate cancer. Those researchers verified a 
general up-regulation of miRNAs in cancer tissue. However, 
6 miRNAs were down-regulated in their study. Conversely, 
Porkka et al. [40] observed a down-regulation for 37 miRNAs 
and an up-regulation for 14 miRNAs in prostate cancer. In the 
Porkka study, they suggested that genetic aberrations might 
target miRNAs and found that miRNA expression in lymph 
nodes could be classified according to their androgen depen-
dence. In addition, Ozen et al. [41] found widespread down-
regulation of miRNAs in prostate cancer tissues. In the studies 
of Porkka et al. [40] and Ozen et al. [41], the let-7 family, miR-
16, miR-23, miR-99, miR-125, miR-29, and miR-30 all were 
down-regulated. Ambs et al. [42] found that prostate cancer 
cells expressed higher miR-32 levels than normal prostate 
cells. They demonstrated that miR-32, miR-26a, miR-196a, 
miR-181a, miR-25, miR-93, miR-92, and let-7i all were up-
regulated and also identified some miRNAs associated with 
extraprostatic disease extension, androgen regulation, and 
transcription of protein-coding target genes. These results 
partially agreed with the data found by Volinia et al. [16].
 miRNAs in prostate cancer tissues might be promising bio-
markers that can be used to detect cancer compared to nor-
mal controls. Szczyrba et al. [43] demonstrated that 33 miR-
NAs in prostate cancer tissues either were up-regulated or 
down-regulated more than 1.5-fold compared to that found 
in noncancer tissues. They suggested that miR-143 and miR-
145 can be involved in the development of prostate cancer. 
Furthermore, Mattie et al. [44] showed that miRNA in biopsy 
specimens in prostate cancer patients could be used to sepa-
rate prostate cancer from normal controls by using their high-
throughput miRNA expression profiling.
 miRNAs in cancer tissues might be a useful marker for 
the prognosis of prostate cancer. Tong et al. [45] performed 
paired analysis of 40 prostatectomy specimens (malignant vs. 
noninvolved areas of each specimen) including 20 with bio-
chemical recurrence within 2 years after prostatectomy and 
20 without a recurrence for more than 10 years. They dem-
onstrated that 5 miRNAs (miR-23b, miR-100, miR-145, miR-
221, and miR-222) were down-regulated in cancer tissues, 
which agreed with the results found by Porkka et al. [40]. Also, 
the expressions of miR-135b and miR-194 were increased in 
cancer tissues with early biochemical recurrence. Schaefer 
et al. [46] also investigated the associations of miRNA expres-
sion and clinicopathological data in matches between 76 
prostate cancer tissue samples and samples of adjacent nor-
mal tissues. They identified 10 miRNAs such as miR-16, miR-
31, miR-125b, miR-145, miR-149, miR-181b, miR-184, miR-
205, miR-221, and miR-222 that were down-regulated and 5 
miRNAs such miR-96, miR-182, miR-182*, miR-183, and miR-
375 that were up-regulated. Some miRNA expressions cor-
related with the Gleason score and the tumor stage. miR-96 
expression was associated with a recurrence after surgery. In 
addition, Spahn et al. [47] also analyzed the global expression 
of miRNAs in benign prostatic hyperplasia (BPH) and meta-
static prostate cancer. They found that some miRNAs are on-
comirs and that down-regulation of miR-221 was associated 
with the Gleason score, progression, and recurrence. Fur-
thermore, miRNA signatures in prostate cancer tissues could 
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be a prognostic marker that could be used to independently 
forecast postoperative outcome in later disease stages [48]. 
 Similarly, several studies of mRNA expression signatures 
in cancer tissues have been associated with prognostic pa-
rameters. Cuzick et al. [49] assessed the prognostic value 
of the mRNA expressions of 31 genes involved in cell-cycle 
progression in prostatectomy samples. They demonstrated 
that cell-cycle progression scores and PSA concentration 
were the most important predictors of recurrence, survival, 
and prognosis. In addition, Penney et al. [50] found that 157 
mRNA expression signatures in prostate cancer tissues could 
be used to predict both the Gleason score and the relative risk 
of lethality, which was helpful in the avoidance of overtreat-
ment. 
miRNAs IN THE BODY FLUIDS OF PROS-
TATE CANCER PATIENTS
In the past, researchers suspected that miRNAs were relevant 
to the regulation of cancer-associated genes in tissues. In 
2008, Lawrie et al. [51] first identified the fact that cell-free 
miRNAs in body fluids such as serum might have potential as 
noninvasive diagnostic markers. They found that the expres-
sion levels of miR-155, miR-210, and miR-21 in serum from 
diffuse large B-cell lymphoma patients were significantly 
higher than that found in normal controls. Since then, there 
has been growing interest in circulating miRNAs. Chen et al. 
[18] showed that cell-free miRNAs are present, stable, repro-
ducible, and consistent in the serum and plasma of humans. 
In addition, they found that each disease such as lung cancer, 
colorectal cancer, and diabetes has a specific expression pat-
tern of serum miRNAs. Thus, detection of miRNAs in body 
fluids could serve as potential noninvasive diagnostic bio-
markers of various cancers. 
 In 2008, Mitchell et al. [19] reported that tumor-derived 
miRNAs can enter the circulatory system and can be mea-
sured in serum and plasma as important blood-based bio-
markers of human cancer. They also showed that circulating 
miR-141 was significantly elevated in the sera of prostate 
cancer patients when compared with healthy controls. Their 
report was the first description of circulating miRNA in pa-
tients with metastatic prostate cancer. Recently, the up-regu-
lation of miR-141 in the plasma of metastatic prostate cancer 
patients was confirmed [52]. Brase et al. [53] also found that 
circulating miRNAs (miR-375 and miR-141) were highly de-
tected in patients with advanced disease, and their levels also 
correlated with a high Gleason score or with a positive status 
for the lymph-node. In addition, miRNAs in tumors were sig-
nificantly up-regulated compared to normal tissue. These re-
sults suggested that some miRNAs including miR-141 might 
be the most promising markers correlated with prostate tu-
mor progression. The function of miR-141 in prostate cancer 
cells is poorly understood. Waltering et al. [54] identified that 
miR-141 was up-regulated after castration, and its activation 
induced the increased growth of LNCaP cells. It is possible 
that miR-141 regulates androgen, which plays a critical role in 
the growth of both androgen-dependent and castration-resis-
tant prostate cancer. Therefore, miR-141 may be functionally 
involved in the disease progression of prostate cancer. 
 Circulating miRNAs might be associated with specific clini-
copathological parameters, risk, aggressiveness, staging, and 
disease outcomes. For instance, Mahn et al. [55] analyzed 
circulating miRNA in the serum of patients with localized 
prostate cancer, BPH and healthy controls. They found that 
miR-195 correlated with clinicopathological parameters such 
as surgical margin positivity and the Gleason score, and that 
miR-let7i also correlated with some specific parameters. In 
addition, Shen et al. [56] investigated the plasma miRNAs 
of 82 prostate cancer patients to analyze the association 
between miRNAs and the development and progression of 
prostate cancer. They found that some miRNAs could distin-
guish low- vs. intermediate- vs. high-risk patients of prostate 
cancer and could predict the aggressiveness of prostate can-
cer. Furthermore, Bryant et al. [57] investigated circulating 
miRNAs for their usefulness as biomarkers for the diagnosis, 
staging, and prediction of outcomes. They analyzed the se-
rum and urine of prostate cancer patients and demonstrated 
that some miRNAs were associated with metastasis in pros-
tate cancer. They showed that circulating miRNAs could be 
diagnostic markers in urine samples. Interestingly, Lodes et 
al. [58] found that in as little as 1 mL of serum, sufficient miR-
NAs were present to detect prostate cancer and to discrimi-
nate between normal and prostate cancer patients. These 
results show that miRNAs can be measured and detected as 
biomarkers in small amounts of body fluids. Consequently, 
circulating miRNA expression, according to alterations, may 
be useful biomarkers for clinical diagnosis and prognosis.
PROBLEMS WITH USING miRNAs
miRNAs are one of the most important mediators for tu-
morigenesis, disease progression, and metastasis. Because 
miRNAs are mediated by gene signaling such as deletions, 
amplifications, mutations, and epigenetic alterations of DNA, 
they can affect the synthesis of proteins necessary to develop 
cancer, disease progression, and metastasis to other organs. 
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Hence, miRNAs can be useful clinical diagnostic and prog-
nostic biomarkers. Nevertheless, there are several limitations 
to be overcome before they can be used to replace conven-
tional biomarkers such as PSA, alpha-fetoprotein (AFP), and 
carcinoembryonic antigen (CEA). Of course, established 
biomarkers also have limitations in distinguishing cancer and 
benign disease. Certainly, cancer biomarkers including CEA 
(colon cancer), AFP (HCC), and PSA are also highly detected 
in benign conditions. For example, PSA levels are increased 
in patients with prostatitis and BPH. 
 First, there is no established endogenous (‘housekeep-
ing’) miRNA control to normalize for miRNA levels in body 
fluids. U6 small nuclear RNA is usually used to normalize 
miRNA levels measured in tissues and body fluids. However, 
this miRNA control was found to be somewhat unstable 
compared to some miRNAs and was degraded in serum 
[18,59]. Some studies have used miR-16 and synthetic ver-
sions of Caenorhabditis elegans miRNAs [19,24]. However, 
measurements of miR-16 in serum might be inconsistent. 
Thus, to identify more stable controls for normalization, more 
studies and empirical validation are necessary. Second, the 
mechanism responsible for the release of miRNAs into body 
fluids, such as blood and urine, and its functional role and 
consequence is poorly understood. Only a few studies have 
examined the characteristics and functions of miRNAs in 
body fluids. For example, exosome that contains miRNAs can 
be delivered to other cells and miRNA-protein complexes 
could be the mechanism responsible for the stability of miR-
NAs in body fluids [60,61]. In particular, in cancer patients, 
tumor-derived microvesicles containing miRNAs stimulate 
angiogenesis, tumor progression, and metastasis [62]. There-
fore, further extensive studies are necessary to identify the 
roles and consequences of miRNAs. Third, there have been 
inconsistencies in the analysis results of some miRNAs in 
various cancers. We hope that advances in science and high-
throughput technology can solve these problems.
FUTURE DIRECTIONS
Interest is increasing in the use of miRNAs as diagnostic and 
prognostic biomarkers for cancer treatment. Many studies 
have identified and confirmed the use of miRNAs as biomark-
ers. Furthermore, some miRNAs have therapeutic potential in 
cancer patients [63]. Thus, some researchers are exploring the 
potential for miRNAs as therapeutic molecules. 
 There are many unexplored fields concerning miRNAs and 
prostate cancer and many topics for research in this field. 
Studies of miRNAs in urine have recently increased. Current 
approaches to the detection of cancer and to the prediction 
of its outcome for patients are invasive and unable to detect 
the early stages. Certainly, many studies are necessary to 
establish miRNAs as useful diagnostic biomarkers in blood 
and urine, and as prognostic biomarkers in cancer tissues. In 
the near future, miRNAs in tissues, blood, and urine will un-
doubtedly be established as new biomarkers for the diagnosis 
and prediction of treatment outcomes in prostate cancer. 
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